ReviewCureus2024

Exploring Esketamine's Therapeutic Outcomes as an FDA-Designated Breakthrough for Treatment-Resistant Depression and Major Depressive Disorder With Suicidal Intent: A Narrative Review.

Suneeta Kumari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.